155 results about "Fat mass" patented technology

A noninvasive method of slimming a patient's body by applying laser energy having a wavelength shorter than 632 nm externally through the skin of the patient. One or more areas of a patient's body, preferably the more fatty regions, such as the abdominal, buttock, lower back, thigh, bust or arm regions, is measured. Objective measurements are made of body criteria, including external dimension, percentage body fat, fat mass, or body mass. Sufficient laser energy, preferably in a range of 0.03-0.1 J / cm2, is applied to one or more of those areas to cause a reduction in the measurement in the lasered areas, as well as overall body slimming. The preferred embodiments use laser light at about 532 nm, 440 nm, or 405 nm. Preferably 18 mW or 25 mW laser diodes are used to apply laser energy at 0.03-0.1 J / cm2 for 15 minutes, every other day for 1-4 weeks, depending on the amount of slimming desired.

An object of the present invention is to provide an easy-understandable representation of fat tissue and lean tissue respectively occupying in a body constitution of a subject. Another object thereof is to help the subject determine which one of the fat tissue or the lean tissue is decreasing by weight reduction. A body type determination apparatus according to the present invention calculates an index of body fat mass, FMI (Fat Mass Index: fat mass / body height2), an index of lean mass, LMI (Lean Mass Index: lean mass / body height2), and a body build index, BMI (Body Mass Index: body weight / body height2) from entered body data and a measured bioelectric impedance, and further the apparatus displays a relationship between the BMI and the FMI and / or between the BMI and the LMI as a result of measurement by way of a graph and / or an illustration.

An object of the present invention is to provide an easy-understandable representation of fat tissue and lean tissue respectively occupying in a body constitution of a subject. Another object thereof is to help the subject determine which one of the fat tissue or the lean tissue is decreasing by weight reduction. A body type determination apparatus according to the present invention calculates an index of body fat mass, FMI (Fat Mass Index: fat mass / body height2), an index of lean mass, LMI (Lean Mass Index: lean mass / body height2), and a body build index, BMI (Body Mass Index: body weight / body height2) from entered body data and a measured bioelectric impedance, and further the apparatus displays a relationship between the BMI and the FMI and / or between the BMI and the LMI as a result of measurement by way of a graph and / or an illustration.

An exercise aid device has a hip supporting member movable relative to a base, footrests movable relative to the base, drive means for driving the hip supporting member, body constitution estimating unit for estimating at least one of fat mass and muscle mass of a user, and a controller for the drive means. The controller controls the drive means such that a load acting on a femoral region by own weight of the user supported on the hip supporting member changes according to a relative positional displacement between the user's toe and trochanter major, the positional displacement is allowed in a direction of flexion and extension of knee joint of the user, and an angle of the knee joint is maintained substantially constant. In addition, since the controller controls the drive means by use of an output of the body constitution estimating unit, it is possible to provide an exercise with less burden to the knee joint and a suitable strength for the user.

Method of monitoring energy consumption of an individual in an information system, comprised of periodically determining the energy balance of the individual by measuring body fat percentages (or body fat mass) at least at three consecutive moments of time and calculating change of body fat percentages (body fat mass) from two consecutive moments of time, and calculating the trends of the individual's energy balance from the changes of body fat percentages (body fat mass) and determining from the trend whether the individual is in the stage of burning or accumulating fat. The information system automatically generates recommendations for controlling energy balance based on the trends of changes of the energy balance.

An exercise aid device has a hip supporting member movable relative to a base, footrests movable relative to the base, drive means for driving the hip supporting member, body constitution estimating unit for estimating at least one of fat mass and muscle mass of a user, and a controller for the drive means. The controller controls the drive means such that a load acting on a femoral region by own weight of the user supported on the hip supporting member changes according to a relative positional displacement between the user's toe and trochanter major, the positional displacement is allowed in a direction of flexion and extension of knee joint of the user, and an angle of the knee joint is maintained substantially constant. In addition, since the controller controls the drive means by use of an output of the body constitution estimating unit, it is possible to provide an exercise with less burden to the knee joint and a suitable strength for the user.

An injectable decellularized fat-matrix microparticle and applications thereof in implants are disclosed. The microparticle is prepared by rinsing, disinfecting and rising fat mass, performing repeated freezing-thawing, cutting the fat mass into slices, soaking the slices, degreasing, decellularizing, performing freeze-drying, and performing low-temperature grinding. The microparticle can be cooperated with an implant auxiliary and adopted as an injectable decellularized fat-matrix microparticle implant. The microparticle has advantages of good biocompatibility, capability of promoting tissue regeneration, and the like. As the microparticle has a three-dimensional structure, the microparticle can be adopted as a support for supporting tissue and cell growth. Active components of the microparticle can induce and regulate cell adhesion, growth, proliferation and differentiation and can promote tissue repairing and regeneration. The implant can be adopted as a minimally invasive plastic injection implanting material, and the implant has a filling function and a tissue repairing function as the natural three-dimensional structure and a lot of the active components of fat are preserved.

The invention provides use of 2-(substituted phenylamino) benzoic acid and ester compound thereof in preparation of an FTO (Fat Mass and Obesity-Associated Protein) inhibitor. The invention particularly discloses the use of 2-(substituted phenylamino)-benzoic acid and the ester compound and a pharmaceutically acceptable salt thereof which are shown in the formula I in preparation of the FTO inhibitor or a pharmaceutical composition for treating FTO-related diseases.

The present invention relates to a nutritional composition comprising an oligosaccharide mixture, said oligosaccharide mixture comprising at least one N-acetylated oligosaccharide, one galacto-oligosaccharide and one sialylated oligosaccharide for use in reducing and / or avoiding excessive fat mass accumulation and / or in preventing anyrelated later in life health disordersin an infant or a young child such as later in life obesity and related comorbidities, by increasing colonic SCFA production and / or GLP-1 secretion / releasein said infant or young child.

The invention relates to a device for processing an edible product in the form a viscous to pasty mass (1), especially an edible product based on a fat mass, such as chocolate, or based on water, such as ice cream. Said device comprises a dosing unit (2) for the dosed delivery of a specific volume of the mass (1) to shaping units (13). The movement of the displacement element (6) determining the dosage volume is performed via servo drive (9) while an inlet (4) and an outlet (5) are closed and opened via servo drive or pneumatic drive, respectively. Preferably, the displacement element is embodied as a combined lifting / rotating plunger (6) which can perform a linear movement for a suctioning lift and a dosing lift while being able to perform a rotary movement for opening and closing the inlet (4) and the outlet (5), i.e. a valve function.

This invention provides human mtDNA polymorphisms that are diagnostic of all the major human haplogroups and methods of diagnosing those haplogroups and selected subhaplogroups. This invention also provides methods for identifying evolutionarily significant mitochondrial DNA genes, nucleotide alleles, and amino acid alleles. Evolutionarily significant genes and alleles are identified using one or two populations of a single species. The process of identifying evolutionarily significant nucleotide alleles involves identifying evolutionarily significant genes and then evolutionarily significant nucleotide alleles in those genes, and identifying evolutionarily significant amino acid alleles involves identifying amino acids encoded by all nonsynonymous alleles. Synonymous codings of the nucleotide alleles encoding evolutionarily significant amino acid alleles of this invention are equivalent to the evolutionarily significant amino acid alleles disclosed herein and are included within the scope of this invention. Synonymous codings include alleles at neighboring nucleotide loci that are within the same codon. This invention also provides methods for associating haplogroups and evolutionarily significant nucleotide and amino acid alleles with predispositions to physiological conditions. Methods for diagnosing predisposition to LHON, and methods for diagnosing increased likelihood of developing blindness, centenaria, and increased longevity that are not dependent on the geographical location of the individual being diagnosed are provided herein. Diagnosis of an individual with a predisposition to an energy metabolism-related physiological condition is dependent on the geographic region of the individual. Physiological conditions diagnosable by the methods of this invention include healthy conditions and pathological conditions. Physiological conditions that are associated with haplogroups and with alleles provided by this invention include energetic imbalance, metabolic disease, abnormal energy metabolism, abnormal temperature regulation, abnormal oxidative phosphorylation, abnormal electron transport, obesity, amount of body fat, diabetes, hypertension, and cardiovascular disease.

The present invention relates to methods to identify factors associated with muscle growth, angiogenesis, obesity, insulin sensitivity body weight, fat mass, muscle mass and cardiovascular function. In particular, the methods of the present invention relates to assays to identify such factors using a transgenic animal model and / or a cell-based assay.

The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and / or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of food intake, stimulation of weight gain, or increasing body fat mass, or increasing body lean mass. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to the use of a ghrelin splice variant-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to a number of new ghrelin splice variant-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin splice variant-like compounds.